Top

Published in:

01-06-2014 | Research Article

The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis

Authors: Shujing Shi, Lingyan Qin, Mengqiu Tian, Mao Xie, Xiaoxue Li, Chenglin Qi, Xiang Yi

Published in: Tumor Biology | Issue 6/2014

Abstract

Genetic polymorphisms of RAD51 135 G>C and XRCC2 G>A (rs3218536) have been reported to change the risk of ovarian cancer, but the results are controversial. To get a more precise result, a meta-analysis was performed. A comprehensive literature search in PubMed, Excerpta Medica Database, and China National Knowledge Infrastructure was carried out to get case–control studies published up to November 2013. The pooled odds ratio (OR) and its corresponding 95 % confidence interval (CI) were conducted to estimate the effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk. A total of 13 independent case–control studies with 5,927 cases and 10,303 controls were included in this meta-analysis. There was no significant association between RAD51 135 G>C polymorphism and risk of ovarian cancer. However, the result of total studies indicated the XRCC2 G>A (rs3218536) polymorphism could reduce the risk of ovarian cancer (heterozygote model AG vs. GG: OR = 0.877, 95 % CI = 0.770–0.999, P = 0.048; dominant model AA/AG vs. GG: OR = 0.864, 95 % CI = 0.763–0.979, P = 0.022). The result was still significant after Hardy–Weinberg equilibrium-violating studies were excluded (allele contrast A vs. G: OR = 0.836, 95 % CI = 0.74–0.943, P = 0.004; homozygote model AA vs. GG: OR = 0.562, 95 % CI = 0.317–0.994, P = 0.048; heterozygote model AG vs. GG: OR = 0.859, 95 % CI = 0.753–0.98, P = 0.023; dominant model AA/AG vs. GG: OR = 0.842, 95 % CI = 0.74–0.958, P = 0.009). In the stratified analysis by ethnicity, significantly reduced risk was observed among Caucasians in dominant model (AA/AG vs. GG: OR = 0.867, 95 % CI = 0.764–0.984, P = 0.027). No significant association was found between the RAD51 135G>C polymorphism and the risk of ovarian cancer. Interestingly, XRCC2 G>A (rs3218536) polymorphism might reduce the risk of ovarian cancer. Larger-scale and well-designed studies are needed to further clarify the association.

Romero I, Bast Jr RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153(4):1593–602.PubMedCentralCrossRefPubMed

Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol. 2003;15(1):63–8.CrossRefPubMed

Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood). 2004;229(6):546–52.

Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? Lancet. 1971;2(7716):163.CrossRefPubMed

Godwin AK et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst. 1992;84(8):592–601.CrossRefPubMed

Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol. 2000;36(4):311–27.CrossRefPubMed

Thacker J. A surfeit of RAD51-like genes? Trends Genet. 1999;15(5):166–8.CrossRefPubMed

Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005;219(2):125–35.CrossRefPubMed

Tambini CE et al. The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair (Amst). 2010;9(5):517–25.CrossRef

10.

Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23(7):247–51.CrossRefPubMed

11.

Shinohara A et al. Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat Genet. 1993;4(3):239–43.CrossRefPubMed

12.

Hasselbach L et al. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol. 2005;26(6):589–98.PubMed

13.

Thacker J, Zdzienicka MZ. The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair (Amst). 2004;3(8–9):1081–90.CrossRef

14.

Lin WY et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet. 2011;48(7):477–84.PubMedCentralCrossRefPubMed

15.

Perez LO et al. XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) single nucleotide polymorphisms in cervical cancer risk. Pathol Oncol Res. 2013;19(3):553–8.CrossRefPubMed

16.

Benhamou S et al. DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer. 2004;112(5):901–4.CrossRefPubMed

17.

Jiao L et al. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol. 2008;103(2):360–7.PubMedCentralCrossRefPubMed

18.

Auranen A et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer. 2005;117(4):611–8.CrossRefPubMed

19.

Jakubowska A et al. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2007;16(2):270–5.CrossRefPubMed

20.

Webb PM et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):319–23.CrossRefPubMed

21.

Beesley J et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2557–65.PubMedCentralCrossRefPubMed

22.

Mohamed FZ et al. Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility. Mol Biol Rep. 2013;40(5):3757–68.CrossRefPubMed

23.

Jakubowska A et al. BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat. 2010;119(1):201–11.CrossRefPubMed

24.

Wang WW et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001;10(9):955–60.PubMed

25.

Levy-Lahad E et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A. 2001;98(6):3232–6.PubMedCentralCrossRefPubMed

26.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed

27.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

28.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

29.

Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7(8):889–94.CrossRefPubMed

30.

Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56(4):297–303.CrossRefPubMed

31.

Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316(7129):469. author reply 470-1.PubMedCentralCrossRefPubMed

32.

Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralCrossRefPubMed

33.

Romanowicz-Makowska H et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33(4):406–10.PubMed

34.

Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247–54.CrossRefPubMed

35.

Garcia-Closas M et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(3):536–42.CrossRefPubMed

36.

Trikalinos TA et al. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006;163(4):300–9.CrossRefPubMed

Title: The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis
Authors: Shujing Shi
Lingyan Qin
Mengqiu Tian
Mao Xie
Xiaoxue Li
Chenglin Qi
Xiang Yi
Publication date: 01-06-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1769-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis

Aberrant BLID expression is associated with breast cancer progression

Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer

Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer

Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker

Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer